The chief executive officer of CG Oncology discussed the role of CG0070 in patients who are unresponsive and responsive to Bacillus Calmette-Guerin immunotherapy.
Arthur Kuan
Advertisement
Chief executive officer, CG Oncology
Articles by Arthur Kuan
The first patient in CG Oncology's phase 2 study of CG0070 was dosed in December 2020.
Advertisement
Latest Updated Articles
CG0070: A Genetically Modified Immunotherapy for Non-Muscle Invasive Bladder CancerPublished: July 30th 2021 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
2
Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025
3
Guess the Therapy Answer October 29, 2025
4
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
5
